PatientView | Türkiye insights from Patient Groups: A seat at the pricing table

Survey insights

16 patient group respondents from Türkiye, informed us how they interact and engage with drug regulators to ensure equitable or more affordable access to medicines.

Regularly or sometimes 38%
Other responses 62%

38% of respondents from Türkiye ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators.

Total number of patients reached = ~10.1K

Patients reached by each patient group (3 respondents).

Patient group voices

actions & advocacy

For example, our views were sought regarding medicines intended to be brought to market with the aim of reducing adverse events arising following bone marrow transplantation.

National cancer patient group

actions & advocacy

Pursuing legal action to secure access to Qalsody (tofersen) — a treatment that has received FDA [Food and Drug Administration] and EMA [European Medicines Agency] approval — for Familial ALS [Amyotrophic Lateral Sclerosis] associated with the SOD1 mutation.

National neuromuscular-conditions patient group

Patient group goals

The percentages below highlight how the 6 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.

actions & advocacy

How patient groups get access to medicines

Find out what the goals mean

1 mention

English text	Therapy area	Category	Patients reached	Geo reach	Regulatory engagement	Respondent
Public awareness [on issues of drug pricing]..	Cancer > Cancer: most types	Pricing and affordability advocacy > Engaging in awareness campaigns	5,000	National	Regularly	119068705424
Pursuing legal action to secure access to Qalsody (tofersen) — a treatment that has received FDA [Food and Drug Administration] and EMA [European Medicines Agency] approval — for Familial ALS [Amyotrophic Lateral Sclerosis] associated with the SOD1 mutation.	Neuromuscular > Amyotrophic lateral sclerosis (ALS)	Improving access pathways > Improving access to rare/ultra-rare therapies	5,000	National	Regularly	119058553408
For example, our views were sought regarding medicines intended to be brought to market with the aim of reducing adverse events arising following bone marrow transplantation.	Cancer > Cancer: most types	Diagnosis and medicines delivery > Ensure safe and effective medicine use	100	National	Sometimes	119016436041
Pursuing legal action to secure access to Qalsody (tofersen) — a treatment that has received FDA [Food and Drug Administration] and EMA [European Medicines Agency] approval — for Familial ALS [Amyotrophic Lateral Sclerosis] associated with the SOD1 mutation.	Neuromuscular > Amyotrophic lateral sclerosis (ALS)	Upholding patient rights/improving quality of life > Support in treatment-related legal actions	5,000	National	Regularly	119058553408

GET THE REPORT

Access the full findings

Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.

Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com

Download sample reports

Download country report

Download therapy report